Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Global Oil Traders Fuel Kineta’s Drug Pipeline

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Kineta, Inc. and Hydra, LLC announced the completion of a major investment to add funding to Kineta’s clinical-stage drug programs.

The investment is directed at Kineta’s two lead drug programs - ShK-186, a novel immune-sparing targeted therapeutic focused on autoimmune diseases, and rOAS, a novel pan-viral therapeutic aimed at an array of high-priority contagious pathogens for which there are few effective therapies.

“We are genuinely impressed with Kineta’s leadership and laser-focus on delivering high-caliber R&D to larger global pharmaceutical companies. This is a nimble organization with a track record of development success. Kineta has created a unique, cost-efficient and rational way to move early-stage drug programs into human subjects with a focus on rapidly delivering liquidity. All of these factors went into our investment decision,” explained Jamie Browne, a managing director of Hydra, LLC.

Mr. Browne co-leads Hydra, LLC, along with Ken Backes. Hydra is comprised of 13 recently retired Glencore Ltd. traders. Each Hydra member has committed considerable capital to the new private equity partnership. Hydra is focused on diversified opportunities, including choosing to provide Kineta, Inc., significant funding to make major clinical advancements in two drug development programs.

“Kineta is very pleased to welcome Hydra as a major investor into our clinical-stage programs. This is a team of highly astute investors with broad appreciation for underlying market forces across economic sectors. Their investment is a tremendous vote of confidence for the Kineta model and will enable us to advance our clinical work for two very promising drug candidates,” said Kineta, Inc., President and CEO Charles Magness, Ph.D.

Kineta’s lead program, Shk-186, recently completed phase one studies, successfully positioning it for multiple development pathways for autoimmune diseases. Kineta’s second program, rOAS, is scheduled to enter first-in-human clinical trials later this year. Kineta’s pipeline also contains three additional drug and vaccine adjuvant programs; all have novel mechanisms of action and are aimed at large, global unmet medical needs. Kineta has raised more than $46M since 2008 through grants and private investment. Kineta’s chief business goal is to partner or license clinically validated assets that have achieved pre-specified development milestones to pharmaceutical companies for further clinical development.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos